Oncology Central

Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?


Acute myeloid leukemia (AML) is a clinically, biologically, molecularly diverse and highly aggressive hematologic malignancy characterized by clonal expansion of immature myeloid precursors, or blasts, in the blood and bone marrow. Despite current treatments, the long-term overall survival (OS) rates are only approximately 40% for younger (<60 years) and approximately 10% for older (>60 years) AML patients [1].

To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.